Key Features

• According to the vendor, the Rapid Enterprise Platform spans neurovascular (ischemic stroke, hemorrhagic/neurocritical, aneurysm), cardiac and vascular (aortic, pulmonary embolism), radiology (Navigator Pro for case prioritization and autoreporting), and life-sciences/clinical-trial support modules.
• The vendor states its core AI functions include triage/notification, anatomical localization, automated quantification (e.g., blood flow, lesion growth), severity/morphology characterization, 3D visualization, and longitudinal tracking across scans.
• The vendor's mobile app pushes real-time notifications of suspected findings, lets clinicians review AI outputs and source imaging in a DICOM viewer, and supports in-app care-team messaging and single-touch initiation of procedural workflows, per the vendor's product page.
• Multiple individual RapidAI products carry independently confirmed FDA 510(k) clearances, reported across several trade-press outlets over multiple years including Rapid NCCT Stroke (2023, described in press coverage as the first FDA-cleared device to detect suspected ICH/LVO from non-contrast CT), Rapid PE Triage & Notification (2022), and Lumina 3D (2025, automated 3D head/neck CTA reconstruction). In late November 2025, RapidAI announced FDA 510(k) clearance for a batch of five additional imaging modules including Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement per the company's own press release and confirmed by most trade-press outlets covering the announcement (one outlet's headline described this batch as "four" clearances, omitting Rapid Aortic, but the primary source and the majority of coverage confirm five). The vendor's site states it holds "30 FDA cleared" modules in total.
• The vendor states its research base includes 750+ peer-reviewed publications and 11 New England Journal of Medicine publications; these publication-count figures are vendor-stated and were not independently re-tallied in this research, though RapidAI's underlying stroke-imaging technology (developed by founder Dr. Gregory Albers) is well documented in stroke-research literature.

Compliance & Security

• HIPAA Compliance: Yes, according to the vendor's Enterprise Infrastructure page, which states the platform "is HIPAA compliant" as part of a listed compliance stack.
• FDA Status: Cleared (510(k)), but on a per-product basis, not as a single blanket clearance for the whole platform. Individual modules (Rapid NCCT Stroke, Rapid PE Triage & Notification, Lumina 3D, Rapid LMVO, Rapid MLS, Rapid DeltaFuse, Rapid OH, Rapid Aortic, and others) each carry their own FDA 510(k) clearance, independently confirmed via multiple trade-press outlets (Diagnostic Imaging, Axis Imaging News, NeuroNews International, AuntMinnie, ITN) reporting on RapidAI's own press releases across 2022–2025. Buyers should confirm the specific clearance status of each individual module they intend to purchase/deploy rather than assuming the entire platform is uniformly cleared.
• Security certifications: According to the vendor, the platform is built on the NIST cybersecurity framework and holds GDPR compliance, ISO 13485, ISO 27001, ISO 27701, ISO 42001, SOC 2 Type 2, and CSA STAR certifications, with badge graphics for each displayed on the vendor's Enterprise Infrastructure page.

Integration & Workflow

• The vendor states standards-based interoperability with PACS, RIS, and EHR systems generally, and describes the underlying "Rapid Edge Cloud" as a hybrid cloud/on-premises infrastructure with on-prem fallback if cloud connectivity is interrupted.
• Platform: Enterprise cloud/hybrid-cloud deployment (Rapid Edge Cloud) integrated into PACS/RIS/EHR workflows, plus a companion native mobile app (iOS/Android implied by "Rapid mobile app" references) for real-time alerts, DICOM review, and care-team coordination.
• Onboarding/setup: The vendor describes a dedicated "Implementation" service ("partners with you to optimize workflows...with hands-on support") and a "Rapid U" professional education/training portal, but no specific implementation timeline was stated.

Pricing & Access

• Not publicly listed; the vendor directs prospective customers to "Request a Demo".
• No free trial is advertised on the vendor's public site.

Doxiverse Assessment: Strengths & Limitations

• Strengths: RapidAI has a deep and independently verifiable regulatory and evidence base for this category, a long, multi-year, multi-product track record of FDA 510(k) clearances, a stated large-scale peer-reviewed publication base, and named enterprise deployments at recognizable health systems (e.g., Ascension, Stanford Health Care, Mayo Clinic, HCA Healthcare, Intermountain Health, appearing as named client logos on the vendor's own site, alongside additional named systems such as Corewell Health, Atrium Health, UChicago Medicine, Trinity Health, Providence, and CommonSpirit).
• Limitations/Risks: Because the platform spans many distinct FDA-cleared modules rather than one blanket clearance, buyers must verify which specific modules are cleared for which specific clinical use before deployment the vendor's "30 FDA cleared" summary figure is a vendor-stated aggregate that a buyer's own regulatory/compliance team should verify against the FDA's public 510(k) database for the exact module(s) being purchased. Pricing is entirely non-public, requiring a sales engagement typical of enterprise-scale imaging AI platforms, and the platform is explicitly positioned as an enterprise-wide, multi-department deployment rather than a lightweight single-purpose tool, which may be a heavier lift (and potential single-vendor dependency across neurovascular, cardiac/vascular, and radiology service lines) for smaller or single-specialty buyers.

Ideal User Profile

• Best for: Hospitals and health systems, particularly comprehensive stroke centers, trauma centers, and larger multi-site systems that want a single enterprise-wide imaging AI platform spanning neurovascular, cardiac/vascular, and general radiology workflows, given its named large-health-system client base and broad FDA-cleared module portfolio.
• Not ideal for: Smaller, single-site facilities or specialty-limited practices seeking one narrow point solution rather than a multi-module enterprise platform, or buyers who need fully transparent, publicly posted pricing before initiating a sales conversation.

Disclaimer - This profile was compiled from publicly available sources including the vendor's own website, regulatory filings, press coverage, and independent research as of July 2026. Vendor claims are labeled as such and have not been independently audited by Doxiverse. Product features, pricing, certifications, and regulatory status change frequently and may no longer be current; verify all details directly with the vendor before making a purchasing decision. The "Doxiverse Assessment" and "Ideal User Profile" sections reflect Doxiverse's independent editorial analysis based on available sources at the time of writing, not the vendor's endorsement, and the vendor may disagree with this characterization. This profile is provided for informational purposes only and does not constitute a recommendation, endorsement, or professional/legal/clinical advice. Report inaccuracies to contact@doxiverse.com